IVIXF

Healthcare Drug Manufacturers - Specialty & Generic

Invion Limited

$0.04

-0.00 -0.00% today

Price History

Not enough data

Key Stats

Market Cap

4.03M

Avg Volume

EPS

-$0.07

52W High

$0.04

52W Low

$0.00

Div. Yield

0.0%

Valuation

P/B Ratio

1.07

P/S Ratio

10.47

EV/EBITDA

-1.26

EV/Revenue

12.96

Margins

Gross Margin (285.4%)

Operating Margin (567.1%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

12675.9%

Return on Equity

(83.0%)

Return on Assets

(40.1%)

Liquidity & Leverage

Current Ratio

0.24

Quick Ratio

0.21

Debt / Equity

0.29

Total Cash

592,311

Total Debt

1.55M

About

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.